KOPRAN vs MOREPENLAB: Stock Comparison

KOPRAN vs MOREPEN LAB.Updated 4 Sept 26, 4:08 PM ISTNSE & company filings

MOREPEN LAB. is the larger company by market capitalisation. KOPRAN shows a lower P/E and a higher dividend yield, while MOREPEN LAB. shows a higher ROE, faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

KOPRAN leads 5; MOREPENLAB leads 8 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

KOPRANMOREPENLAB

Valuation lens

What price are you paying?

Market CapContext only
₹1,120 Cr
₹6,230 Cr
P/E RatioKOPRAN has the lower reading
37.34x
44.1x
P/B RatioKOPRAN has the lower reading
1.76x
4.96x
EPSKOPRAN has the higher reading
₹1.39
₹0.99
Book ValueContext only
₹109.82
₹22.76
Dividend YieldKOPRAN has the higher reading
2.76%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
MOREPENLAB is the larger company
₹6,230 Cr vs ₹1,120 Cr
P/E Ratio
KOPRAN has a lower P/E
37.34x vs 44.1x
P/B Ratio
KOPRAN has a lower P/B
1.76x vs 4.96x
EPS
KOPRAN has higher earnings per share
₹1.39 vs ₹0.99
Dividend Yield
KOPRAN has a higher dividend yield
2.76% vs 0%
Revenue Growth (TTM YoY)
MOREPENLAB has faster revenue growth
4% vs -3.66%
EPS Growth (TTM YoY)
MOREPENLAB has faster EPS growth
-18.9% vs -71.88%
Qtr Sales Growth
MOREPENLAB has stronger quarterly sales growth
-5.1% vs -59.25%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricKOPRANMOREPENLAB
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricKOPRANMOREPENLAB
Live Price₹232.54₹113.74
Day Change0.13%-3.16%
Volume6.61 L1.76 Cr
52-Week High₹239.6₹118.55
52-Week Low₹107₹33.05
Distance from 52W High-2.95%-4.06%

Valuation

MetricKOPRANMOREPENLAB
Market Cap₹1,120 Cr₹6,230 Cr
P/E Ratio37.34x44.1x
P/B Ratio1.76x4.96x
EPS₹1.39₹0.99
Book Value₹109.82₹22.76
Dividend Yield2.76%0%

Growth

MetricKOPRANMOREPENLAB
Revenue Growth (TTM YoY)-3.66%4%
EPS Growth (TTM YoY)-71.88%-18.9%
Qtr Sales Growth-59.25%-5.1%
Qtr Profit Growth0.33%-4.26%

Profitability & Leverage

MetricKOPRANMOREPENLAB
ROE4.85%7.61%
ROCE4.89%7.71%
Net Margin3.78%5.25%
Operating Margin6.58%7.55%
Debt to Equity0.29x0.16x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricKOPRANMOREPENLAB
Promoter Holding44.42%35.65%
FII Holding0.51% 0.06 pp1.46% 0.12 pp
DII Holding0%1.28% 0.03 pp
Public Holding55.06% 0.06 pp61.59% 0.09 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: KOPRAN and MOREPEN LAB..

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.